Clinical Trial Update: Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma [Phase 2]

View source ↗

Summary

Phase 2 trial update on OC000459 for eosinophilic airway inflammation in severe asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Asthma

Drugs mentioned

• OC000459

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Severe Eosinophilic Asthma | Phase 2 | Status: COMPLETED